Contrasting of Mesoblast Limited (MESO) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)

This is a contrast between Mesoblast Limited (NASDAQ:MESO) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) based on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mesoblast Limited 16.45M 30.38 89.91M -0.90 0.00
Corbus Pharmaceuticals Holdings Inc. 5.76M 76.69 70.21M -0.98 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents Mesoblast Limited (NASDAQ:MESO) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Mesoblast Limited -546.57% -16% -12.5%
Corbus Pharmaceuticals Holdings Inc. -1,218.92% -102.5% -76.8%

Risk & Volatility

Mesoblast Limited has a 1.81 beta, while its volatility is 81.00% which is more volatile than Standard and Poor’s 500. Competitively, Corbus Pharmaceuticals Holdings Inc. is 106.00% more volatile than Standard and Poor’s 500, because of the 2.06 beta.

Liquidity

The Current Ratio of Mesoblast Limited is 2.9 while its Quick Ratio stands at 2.9. The Current Ratio of rival Corbus Pharmaceuticals Holdings Inc. is 2.4 and its Quick Ratio is has 2.4. Mesoblast Limited is better equipped to clear short and long-term obligations than Corbus Pharmaceuticals Holdings Inc.

Analyst Recommendations

The Ratings and Recommendations for Mesoblast Limited and Corbus Pharmaceuticals Holdings Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Mesoblast Limited 0 0 0 0.00
Corbus Pharmaceuticals Holdings Inc. 0 0 4 3.00

Competitively Corbus Pharmaceuticals Holdings Inc. has an average price target of $27, with potential upside of 294.16%.

Insider & Institutional Ownership

The shares of both Mesoblast Limited and Corbus Pharmaceuticals Holdings Inc. are owned by institutional investors at 2.7% and 37.1% respectively. Competitively, Corbus Pharmaceuticals Holdings Inc. has 4.9% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Mesoblast Limited -2.05% -8.36% 23.19% -30.61% -4.54% 27.67%
Corbus Pharmaceuticals Holdings Inc. -2.38% 3.21% -10.86% 11.8% 28.52% 26.54%

For the past year Mesoblast Limited has stronger performance than Corbus Pharmaceuticals Holdings Inc.

Summary

On 8 of the 11 factors Mesoblast Limited beats Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.